Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China()

BACKGROUND: Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged <12 years has not been fully documented. We evaluated the therapeutic efficacy and safety of omalizumab in Chinese CSU population across all age grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ao, Yun, Yuhui, Wen, Zhihua, Gao, Yingxia, Qi, Shuzhen, Zhang, Yu, Liang, Yunsheng, Yao, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2022
Materias:
Full-Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672950/
https://www.ncbi.nlm.nih.gov/pubmed/36438194
http://dx.doi.org/10.1016/j.waojou.2022.100719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672950/
https://www.ncbi.nlm.nih.gov/pubmed/36438194
http://dx.doi.org/10.1016/j.waojou.2022.100719

Ejemplares similares